enVVeno Medical Corp Dossier
Qualitative Analysis
Business overview
enVVeno Medical Corporation (NASDAQ: NVNO) is an Irvine, California-based, clinical-stage medical device company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The company's primary focus is on its next-generation, non-surgical venous valve product, called the enVVe® System. The enVVe System consists of the enVVe Valve, enVVe Delivery System, enVVe Nose Cone, the enVVe Delivery System Accessories, and the enVVe Crimping System. It is designed as a transcatheter-delivered, first-in-class replacement venous valve for the treatment of severe Deep Venous Insufficiency (DVI). The procedure is performed under light sedation and does not require an overnight hospital stay. Previously, the company developed the VenoValve®, a surgical replacement venous valve, but received a not-approvable letter from the FDA in August 2025, shifting its strategic focus to the transcatheter enVVe System.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Accelerating the development of the enVVe System, a less invasive, transcatheter-based approach designed to address prior regulatory considerations while broadening the potential physician adoption base.
Expected impact: Provides a less invasive, transcatheter-based approach that broadens potential physician adoption and addresses prior regulatory considerations.
Pursuing a supervisory appeal process and active discussions with FDA leadership to establish a clear regulatory and commercial path for the surgical VenoValve.
Expected impact: Unlocks the commercial potential of the surgical VenoValve for millions of patients suffering from severe deep CVI.